Design of novel Geldanamycin analogue hsp90 alpha-inhibitor in silico for breast cancer therapy

Medical Hypotheses

Volumn 81, Issue 3, 2013, Pages 463-469

  Mahanta, Sailendra ^a   Pilla, Smita ^a   Paul, Subhankar ^a  

^a NATIONAL INSTITUTE OF TECHNOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

GELDANAMYCIN; HEAT SHOCK PROTEIN 40; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; PROTEIN P53;

ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER CHEMOTHERAPY; COMPUTER MODEL; CONFORMATIONAL TRANSITION; DRUG BINDING; DRUG DESIGN; DRUG EFFICACY; DRUG SOLUBILITY; HUMAN; HYDROGEN BOND; HYPOTHESIS; MOLECULAR DOCKING; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN PROCESSING; PROTEIN STRUCTURE; WILD TYPE;

ANTINEOPLASTIC AGENTS; BENZOQUINONES; BREAST NEOPLASMS; COMPUTER SIMULATION; DRUG DESIGN; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; PROTEIN BINDING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84881553124     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2013.06.012     Document Type: Article

References (20)

1. Ferlay J., Shin H.-R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
2. Pick E., Kluger Y., Giltnane J.M., Moeder C., Camp R.L., Rimm D.L., et al. High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res 2007, 67:2932-2937.
3. Neckers L., Neckers K. Heat-shock protein 90 inhibitors as novel cancer chemotherapeutic agents. Expert Opin Emerg Drugs 2002, 7:277-288.
4. Levine A.J., Oren M. The first 30years of p53: growing ever more complex. Nat Rev Cancer 2009, 9:749-758.
5. Trepel J., Mollapour M., Giaccone G., Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 2010, 10:537-549.
6. Dutta R., Inouye M. GHKL, an emergent ATPase/kinase superfamily. Trends Biochem Sci 2000, 25:24-28.
7. Sreedhar A.S., Kalmar E., Csermely P., Shen Y.F. Hsp90 isoforms: functions, expression and clinical importance. FEBS Lett 2004, 562:11-15.
8. Bergerat A., de Massy B., Gadelle D., Varoutas P.C., Nicolas A., Forterre P. An atypical topoisomerase II from Archaea with implications for meiotic recombination. Nature 1997, 386:414-417.
9. Wayne N., Bolon D.N. Dimerization of Hsp90 is required for in vivo function. Design and analysis of monomers and dimers. J Biol Chem 2007, 282:35386-35395.
10. Pratt W.B., Morishima Y., Peng H.M., Osawa Y. Proposal for a role of the Hsp90/Hsp70-based chaperone machinery in making triage decisions when proteins undergo oxidative and toxic damage. Exp Biol Med (Maywood) 2010, 235:278-289.
11. Harris C.C. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 1996, 88:1442-1455.
12. Kubbutat M.H., Jones S.N., Vousden K.H. Regulation of p53 stability by Mdm2. Nature 1997, 387:299-303.
13. Peng Y., Chen L., Li C., Lu W., Chen J. Inhibition of MDM2 by hsp90 contributes to mutant p53 stabilization. J Biol Chem 2001, 276:40583-40590.
14. Mimnaugh E.G., Chavany C., Neckers L. Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J Biol Chem 1996, 271:22796-22801.
15. Okamoto J., Mikami I., Tominaga Y., Kuchenbecker K.M., Lin Y.C., Bravo D.T., et al. Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesothelioma. J Thorac Oncol 2008, 3:1089-1095.
16. Pashtan I., Tsutsumi S., Wang S., Xu W., Neckers L. Targeting Hsp90 prevents escape of breast cancer cells from tyrosine kinase inhibition. Cell Cycle 2008, 7:2936-2941.
17. Morris G.M., Huey R., Lindstrom W., Sanner M.F., Belew R.K., Goodsell D.S., et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem 2009, 30:2785-2791.
18. Jensen M.R., Schoepfer J., Radimerski T., Massey A., Guy C.T., Brueggen J., et al. NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models. Breast Cancer Res 2008, 10:R33.
19. Neckers L. Heat shock protein 90 is a rational molecular target in breast cancer. Breast Dis 2002, 15:53-60.
20. Sidera K., Gaitanou M., Stellas D., Matsas R., Patsavoudi E. A critical role for HSP90 in cancer cell invasion involves interaction with the extracellular domain of HER-2. J Biol Chem 2008, 283:2031-2041.